In-Med Prognostics announces Oncohield CT Tool for liver and pancreatic cancers

In-Med Prognostics announces Oncohield CT Tool for liver and pancreatic cancers

Pune, March 26, 2024: In-Med AI announces “Oncoshield” CT tool for clinical decision support in diagnosing and treating liver and pancreatic cancers. In-Med is a proven leader in developing AI/ML tools for multimodal analytics and radiology in the healthcare field.

In-Med Oncoshield software automatically detects and quantifies lesions in liver and pancreas in CT scans. It automatically calculates volumes and identifies locations of lesions. This significantly enhances diagnostic capabilities and improves patient care especially in preparing for surgery. These insights are produced with over 90% accuracy and very speedily in a matter of minutes.

Medical imaging is integral to the early diagnosis and treatment of liver and pancreatic cancers. Global estimates indicate approximately close to a million new cases of liver cancer (hepatocellular carcinoma – HCC) are diagnosed annually. Pancreatic and liver cancers lead the list in lowest survival rates at 13% and 21% respectively. Therefore, early detection and accurate diagnosis are essential for enhancing patient outcomes. In-Med’s Oncoshield assists radiologists in the early detection of liver lesions. Early detection is crucial for prompt medical intervention and improved patient outcomes.

Quantitative assessment, volume calculation, and density analysis is crucial for treatment planning and monitoring. These analyses are helpful in distinguishing between benign and malignant liver lesions, providing a quantitative foundation for reliable and accurate diagnosis. In cases where surgical intervention or interventional radiology treatments are required, Oncoshield provides valuable information for treatment planning.  It can help surgeons understand the location, size, and characteristics of lesions, aiding in decision making for the best course of action. By identifying lesions early, Oncoshield can help clinicians better stratify patients based on their risk, allowing for more personalized treatment plans.

Cancer treatment is usually accompanied by regular imaging for monitoring the progression of liver diseases. Given the paucity of radiologists and their notorious burnout, increased frequency of scans adds to their workload. In-Med’s Oncoshield can reduce radiologist workload through automated analysis and allows healthcare professionals such as oncologists and hepatologists to assess the effectiveness of treatments and make necessary adjustments using quantitative measures in a longitudinal fashion over time. While final diagnosis and treatment decisions should always involve human healthcare professionals, these AI tools can be invaluable help to radiologists and other clinicians in giving the best possible care to their patients on a timely basis.

Oncoshield can be used in medical research and clinical trials to analyze large datasets of CT liver scans. This can contribute to better understanding of liver diseases, treatment outcomes, and development of new therapies and reduce drug development and time to market for pharma and life sciences companies.

The product is integrated seamlessly into the clinical and radiology workflow and efficiently prioritizes critical cases that require immediate attention. The reports are sent via the radiology information system, email, and phone to the concerned decision makers. The product is currently deployed at the Madras Medical College and the company is offering 30-day free trial to prospective customers and 90-day free trials to its current customers who may be using Neuroshield.

Rahim Pathan, In-Med’s Head of Development Center, said, “At In-Med, innovation is our compass, guiding us toward a future where healthcare is smarter, more accessible, and more compassionate. Our commitment extends beyond mere software development; we are dedicated to pioneering transformative solutions that revolutionize healthcare, one breakthrough after another.”

Dr. Latha Poonamallee, Founder and CEO of In-Med, added, “At In-Med AI, our mission is to capture the untapped potential of AI in healthcare by leveraging multimodal data across the globe. Our solutions are tailored to each individual with a commitment to inclusion and innovation. Together, we can empower the healthcare ecosystem, save radiologists’ time, and produce more precise and more accurate results faster. Our technology empowers healthcare providers to reach all their patients equally. At the same time, we’re accelerating the availability of accurate data for more precise and faster treatment. And we’re elevating the way that providers treat patients so they can focus on impactful, preventative care. I am excited to continue to expand the scope of our contribution to this field.”

This new product follows the pathbreaking Neuroshield MRI Volumetry product targeting neurodegenerative conditions like dementia, Alzheimer’s, Parkinson’s, and Epilepsy and Neuroshield CT TBI products already operational in over 280 sites in India, Africa, and the Middle East. Neuroshield MRI Volumetry recently received the US FDA 510 clearance for sales in the US market. With this new product, In-Med has proven its capacity to expand the applications of its multi modal and multi organ capabilities.

About In-Med: Led by Dr. Latha Poonamallee (Founder & CEO), Dr. Allen Curran (Co-Founder), and Dr. Girish Srinivasan (CTO), In-Med is a globally distributed venture with scientific and development talent in the US, EU, and India. In-Med’s expertise is in translational research, multi-modal medical data analytics including clinical imaging, and development and deployment of AI/ML algorithms. In-Med is supported by seed funding from Mr. Sriram Natarjan of Molbio Diagnostics, an Indian unicorn.


Please enter your comment!
Please enter your name here